Russell Investments Group, Ltd. Anavex Life Sciences Corp. Transaction History

Russell Investments Group, Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$4.55 - $6.75 $131 - $195	29 Added 33.72%	115 $0
Q4 2023 Feb 05, 2024	BUY	$5.04 - $9.95 $433 - $855	86 New	86 $0
Q3 2021 Nov 08, 2021	SELL	$16.82 - $25.75 $1.63 Million - $2.49 Million	-96,766 Reduced 70.24%	41,007 $736,000
Q2 2021 Aug 04, 2021	SELL	$10.16 - $28.86 $1.23 Million - $3.49 Million	-120,802 Reduced 46.72%	137,773 $3.15 Million
Q1 2021 May 10, 2021	SELL	$5.17 - $16.13 $445,457 - $1.39 Million	-86,162 Reduced 24.99%	258,575 $3.86 Million
Q4 2020 Feb 08, 2021	SELL	$4.01 - $7.58 $593,764 - $1.12 Million	-148,071 Reduced 30.05%	344,737 $1.86 Million
Q3 2020 Nov 09, 2020	BUY	$3.8 - $5.0 $1.05 Million - $1.39 Million	277,381 Added 128.76%	492,808 $2.24 Million
Q2 2020 Aug 05, 2020	SELL	$2.62 - $5.2 $68,248 - $135,454	-26,049 Reduced 10.79%	215,427 $1.06 Million
Q1 2020 May 06, 2020	BUY	$2.38 - $5.81 $574,712 - $1.4 Million	241,476 New	241,476 $757,000
Q4 2017 Feb 06, 2018	SELL	$3.12 - $4.94 $59,891 - $94,828	-19,196 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$3.42 - $4.87 $65,650 - $93,484	19,196	19,196 $79,000

163

27.5M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.